Iradimed Stock Earnings Reports

IRadimed reported a strong Q1 2026: revenue of $22.0M (+13% YoY), operating income of $7.2M (+33% YoY) and net income of $5.8M ($0.45 diluted EPS, +22% YoY). Growth was driven by IV infusion pump systems (including fulfillment of 3860 backlog), MRI patient monitoring, and rising contribution from the Ferro-magnetic Detection System. Gross margin was 77%; operating expenses were roughly flat YoY. Cash and equivalents were $56.4M and operating cash flow improved materially (cash from ops $8.3M). The Board declared a quarterly cash dividend of $0.20/share. Management highlighted the new 3870 MRI IV pump as the primary growth catalyst: early orders show a higher-than-expected ASP (closer to +20% vs. prior 10–14% expectation) and an unexpectedly large share of orders for Quad (4-channel) systems, which doubles pump channels per order and materially increases ASP per deal. Management is targeting incremental replacement of ~1,000 pump channels/year from the existing 6,400+ older 3860 channels (U.S. market) with additional upside from greenfield, disposables, maintenance, international sales, MRI monitoring and ferro-magnetic systems. Manufacturing ramp for 3870 will be cautious: target shipping ~130–135 units in Q2, with planned step-up in later quarters. Guidance: Q2 revenue $20.0–21.0M, GAAP EPS $0.40–0.44, non-GAAP EPS $0.44–0.48. Full-year 2026 guidance reaffirmed: revenue $91–96M, GAAP EPS $1.90–2.05, non-GAAP EPS $2.06–2.21. Key near-term investor considerations: accelerated ASP and quad adoption could drive materially higher pump revenue in H2 2026 and beyond, but near-term revenue will reflect a controlled ramp and replacement of declining 3860 sales; the company remains well-capitalized with a shareholder-friendly dividend.